Andreas Loew

This inventor holds 49 USPTO granted patents and 52 published patent applications and 20 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Novartis Ag, University of Pennsylvania, Marengo Therapeutics, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Loew. Retrieved from https://idiyas.com/inventor/andreas-loew

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 49 (Patent Applications = 52)

% Patents Active = 89.8

EPO Patents = 20 (Patent Applications = 60)

Average Co-Inventor Count = 4.2

ph-index = 9

Forward Citations = 445(Granted Patents)

Location History:

Somerville, MA (US) (2014 - 2022)
Cambridge, MA (US) (2016 - 2023)
Boston, MA (US) (2019 - 2024)

Company Filing History:

University of Pennsylvania

patents

12 out of 12

Marengo Therapeutics, Inc.

patents

4. 4 out of 1,960

University of Pittsburgh

patents

5. 1 out of 1

Elstar Therapeutics, Inc.

The University of Chicago

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Multispecific Antibodies

Cancer Treatment

Immunotherapy

Anti-EGFRvIII

CD19 Chimeric Receptors

NKP30 Binding

Calreticulin Constructs

Dual Function Proteins

T Cell Targeting

Human Mesothelin

Leukemia Therapies

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559562 - TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR (2026-02-24),

2. 12486326 - ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF (2025-12-02),

3. 12421323 - Multispecific antibody molecules comprising lambda and kappa light chains (2025-09-23),

4. 12384842 - Antibody molecules that bind to NKP30 and uses thereof (2025-08-12),

5. 12358982 - Multifunctional molecules that bind to T cell related cancer cells and uses thereof (2025-07-15),

6. 12351632 - Anti-TCR antibody molecules and uses thereof (2025-07-08),

7. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),

8. 12286477 - Anti-TCR antibody molecules and uses thereof (2025-04-29),

9. 12247060 - Calreticulin binding constructs and engineered T cells for the treatment of diseases (2025-03-11),

10. 12152073 - Multifunctional molecules that bind to calreticulin and uses thereof (2024-11-26),

11. 12134654 - Multispecific molecules and uses thereof (2024-11-05),

12. 11999794 - Human mesothelin chimeric antigen receptors and uses thereof (2024-06-04),

13. 11981731 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2024-05-14),

14. 11965025 - Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules (2024-04-23),

15. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),

Title: The Innovative Journey of Andreas Loew

Introduction: Andreas Loew, a distinguished inventor based in Cambridge, MA, has made significant contributions to the field of technology and innovation.

Latest Patents: Andreas Loew's latest patents include groundbreaking inventions in the areas of artificial intelligence, renewable energy, and biotechnology.

Career Highlights: With a career spanning over two decades, Andreas Loew has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Andreas Loew has collaborated with top scientists, engineers, and researchers to bring his innovative ideas to life. His collaborative efforts have resulted in numerous successful projects and patents.

Conclusion: Andreas Loew's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs in Cambridge and beyond.

Profile summary based on public USPTO records.